EP2363466B1 - Tannase, gene encoding same, and process for producing same - Google Patents

Tannase, gene encoding same, and process for producing same Download PDF

Info

Publication number
EP2363466B1
EP2363466B1 EP09821747.4A EP09821747A EP2363466B1 EP 2363466 B1 EP2363466 B1 EP 2363466B1 EP 09821747 A EP09821747 A EP 09821747A EP 2363466 B1 EP2363466 B1 EP 2363466B1
Authority
EP
European Patent Office
Prior art keywords
tannase
amino acid
dna
acid sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09821747.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2363466A4 (en
EP2363466A1 (en
Inventor
Megumi Nakagawa
Naoki Matsumoto
Hitoshi Amano
Shotaro Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amano Enzyme Inc
Original Assignee
Amano Enzyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amano Enzyme Inc filed Critical Amano Enzyme Inc
Publication of EP2363466A1 publication Critical patent/EP2363466A1/en
Publication of EP2363466A4 publication Critical patent/EP2363466A4/en
Application granted granted Critical
Publication of EP2363466B1 publication Critical patent/EP2363466B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids

Definitions

  • the present invention relates to novel tannase produced by a microorganism belonging to the genus Aspergillus. Specifically, the invention relates to tannase produced by the genus Aspergillus, which is excellent in thermostability, a gene encoding the tannase, a process for producing the tannase, a use of the tannase, and the like.
  • Tannase (tannin acyl hydrolase, EC3.1.1.20) is an enzyme that hydrolyzes a depside bond of tannins. In the food industry, tannase is used for prevention of cream down in tea beverages, prevention of lee in fruit juice beverages, clarification of beer, and the like.
  • Non-patent Document 1 Production of tannase by bacteria, yeasts, and filamentous fungi has been reported in large numbers so far (Non-patent Document 1). There are many reports about the genus Aspergillus and the genus Penicillium for the filamentous fungi. Chemoenzymatic properties, an amino acid sequence and a gene encoding tannase have been revealed for tannase derived from Aspergillus oryzae (see Patent Documents 1 and 2, and Non-patent Document 2).
  • the tannase described in Patent Document 1 has mild acidity such as an optimum pH range around from 5.0 to 5.5, and an optimum temperature range of around 40°C, and is deactivated within 10 minutes at a high temperature such as higher than 60°C. Therefore, the tannase is reacted under very limited conditions in industrial applications.
  • the tannase described in Patent Document 2 is excellent in thermostability, a residual activity after treatment at 65°C for 10 minutes in a citric acid buffer solution (pH 5.5) is 80% or more, and an optimum temperature range is from 60 to 80°C, and thus, the defect of the tannase described in Patent Document 1 is overcome, but production of a recombinant was only reported and production of a non-recombinant is not confirmed. Therefore, for applications in the food industry, safety confirmation according to "safety evaluation standard of additives produced in use of genetically modified organisms" is required (Non-patent Document 3). In addition, there is deep-seated rejection against genetically modified foods in Japan. Accordingly, the tannase cannot be recognized as one that is immediately applicable in the food industry.
  • thermo stability which has an optimum temperature of 60°C or higher
  • Non-patent Documents 4 and 5 tannase excellent in thermo stability, which has an optimum temperature of 60°C or higher.
  • existence of such tannase has been merely confirmed and the amino acid sequence thereof, a gene encoding the tannase, chemoenzymatic properties thereof, and the like have not been revealed and a practical application has not been achieved yet.
  • An object of the present invention is to provide tannase excellent in thermostability, which is derived from microorganisms existing in the natural world. Another object of the invention is also to provide a gene of the tannase, a process for producing the tannase and a use of the tannase.
  • the present inventors have intensively investigated in order to solve the above-mentioned problems. As a result, production of tannase having high thermostability was observed in totally 5 strains that are 3 strains of Aspergillus niger and 2 strains of Aspergillus awamori. Further investigations proceeded and the present inventors succeeded in isolation of tannase produced by Aspergillus awamori NBRC-4033 (IFO-4033) and determined the chemoenzymatic properties thereof. They also succeeded in identification of the amino acid sequence of the tannase and a base sequence of a gene encoding the tannase. As a result of comparing the chemoenzymatic properties and the amino acid sequence to those of tannase previously reported, the tannase successfully obtained and identified was confirmed to be novel.
  • the present invention was accomplished based on the above-mentioned achievements, and relates to the embodiments as characterized in the claims.
  • the present application also discloses the following.
  • DNA encoding protein in the present invention denotes DNA from which the protein is obtained when it is expressed, that is, DNA having a base sequence corresponding to an amino acid sequence of the protein. Therefore, the codon degeneracy is also taken into consideration.
  • isolated and “purified” are used interchangeably.
  • isolated used with respect to the enzyme of the present invention tannase), which is derived from a natural material, denotes a state in which components other than the enzyme are not substantially contained (in particular, contaminated protein is not substantially contained) in the natural material.
  • the content of the contaminant protein is, for example, less than about 20%, preferably less than about 10%, further preferably less than about 5%, and yet further preferably less than about 1% with respect to the total amount on the weight basis.
  • the term "isolated" when the enzyme of the present invention is prepared by genetically engineering technique denotes a state in which other components derived from a host cell to be used, a culture solution, and the like, are not substantially contained.
  • the content of the contaminant components is less than about 20%, preferably less than about 10%, further preferably less than about 5%, and yet further preferably less than about 1% with respect to the total amount on the weight basis.
  • the term "tannase” when merely the term "tannase” is used in this specification, it signifies the “tannase in an isolated state.” The same is true to the term "the present enzyme” used instead of tannase.
  • isolated used with respect to DNA denotes typically that DNA is separated from other nucleic acid coexisting in nature when the DNA originally exists in nature. However, some of the other nucleic acid components such as a neighboring nucleic acid sequence in nature (for example, a sequence of a promoter region, a terminator sequence, or the like) may be included.
  • the isolated DNA in the “isolated” state of the genome DNA, the isolated DNA preferably does not substantially include other DNA components coexisting in nature.
  • the DNA in the "isolated” state of DNA prepared by a genetic engineering technique, for example, a cDNA molecule, and the like, preferably, the DNA does not substantially include cell components, a culture solution, or the like.
  • the DNA does not include a precursor (a raw material) or chemical materials used in synthesis, for example, dNTP. Unless otherwise specified, when merely the term "DNA” is used in this specification, it signifies the “DNA in an isolated state.”
  • a first aspect of the present invention provides tannase (hereinafter, also referred to as "the present enzyme") and the producing microorganism thereof.
  • the present inventors have intensively investigated; as a result, they found that Aspergillus awamori and Aspergillus niger produced thermostable tannase resistant to a thermal treatment at 65°C. Further investigations proceeded and the present inventors succeeded in separation and purification of tannase derived from Aspergillus awamori, and at the same time, succeeded in determination of the chemoenzymatic properties thereof as shown below.
  • the present enzyme is tannase and acts on a depside bond to hydrolyze the depside bond.
  • the present enzyme shows a molecular weight of about 230,000 Da by gel filtration.
  • the present enzyme shows a molecular weight of 90,000 to 100,000 Da by SDS-PAGE.
  • the present enzyme has a sugar chain and shows significant decrease in the molecular weight by an endoglycosidase H (EndoH) treatment.
  • EndoH endoglycosidase H
  • the present enzyme maintains 90% or more of the activity in 50 mM citric acid buffer solution (pH 5.0) at 65°C for 30 minutes.
  • the optimum temperature of the present enzyme is about 70°C.
  • the present enzyme shows high activity at a temperature in the range from about 60°C to about 70°C.
  • the optimum temperature is a value calculated by the below-mentioned measurement method of tannase activity (50mM citric acid buffer solution (pH 5.0)).
  • the optimum pH of the present enzyme is about 5.5.
  • the present enzyme shows high activity in the range from pH about 5.0 to about 6.0.
  • the optimum pH is determined, for example, based on the results of the measurement in a citric acid buffer with respect to pH region of pH 3 to 6 and based on the results of the measurement in a phosphate buffer with respect to pH region of pH 6 to 8.
  • the enzyme shows stable activity in such a wide pH range as pH 3 to 8. That is to say, when pH of an enzyme solution subjected to treatment is within the range, the enzyme shows 80% or more activity with respect to the maximum activity after treatment at 30°C for 30 minutes.
  • the pH Stability is determined, for example, based on the results of the measurement in a citric acid buffer for the pH region of pH 3 to 6, and based on the results of the measurement in a phosphate buffer for the pH region of pH 6 to 8.
  • the present enzyme preferably acts on tannic acid.
  • the enzyme also acts on gallic acid esters (methyl gallate, ethyl gallate, etc.).
  • reactivity and substrate specificity of the present enzyme can be measured and evaluated by methods shown in examples mentioned below (sections for measurement method of tannase activity and measurement method of substrate specificity).
  • the present enzyme is tannase derived from Aspergillus awamori.
  • the "tannase derived from Aspergillus awamori” denotes tannase produced by microorganisms classified in Aspergillus awamori (which may be wild-type strain and mutant strain), or tannase produced by using a tannase gene of Aspergillus awamori (which may be wild-type strain and mutant strain) obtained by a genetic engineering technique.
  • the "tannase derived from Aspergillus awamori” includes a recombinant produced by using a host microorganism into which a tannase gene (or a gene obtained by modifying the gene) obtained from Aspergillus awamori has been introduced.
  • Aspergillus awamori from which the present enzyme is derived is represented by a producing microorganism of the present enzyme for easy description.
  • the present enzyme is excellent in thermostability and excellent in pH Stability. Therefore, the present enzyme is useful for food processing and saccharification.
  • one embodiment of the present invention is characterized in that the present enzyme consists of a protein having an amino acid sequence set forth in SEQ ID NO: 5.
  • the modified protein may sometimes have a function the same as that of the protein before modification. That is to say, the modification of the amino acid sequence does not have a substantial effect on the function of the protein, so that the function of the protein may be maintained before and after the modification.
  • the present invention provides a protein having an amino acid sequence equivalent to the amino acid sequence set forth in SEQ ID NO: 5 and having the tannase activity (hereinafter, which is referred to as "equivalent protein").
  • the "equivalent amino acid sequence” herein denotes an amino acid sequence that is partly different from the amino acid sequence set forth in SEQ ID NO: 5 but this difference does not have a substantial effect on the function (herein, the tannase activity) of the protein.
  • Having the tannase activity denotes an activity of acting on a molecule having a depside bond such as, typically, tannic acid; and gallic acid esters, digallic acid, gallotannin and ellagitannin to hydrolyze the depside bond; however, the degree of the activity is not particularly limited as long as the function of tannase can be exhibited. However, it is preferable that the activity is equal to or higher than that of the protein having the amino acid sequence set forth in SEQ ID NO: 5.
  • the "partial difference in the amino acid sequence” typically denotes that mutation (change) occurs in an amino acid sequence due to deletion or substitution of one to several amino acids constituting the amino acid sequence, or addition or insertion of one to several amino acids, or the combination thereof.
  • the difference in the amino acid sequence is permitted as long as the tannase activity is maintained (more or less change in the activity is permitted).
  • the position in which a difference in the amino acid sequence occurs is not particularly limited and the difference may occur in a plurality of positions.
  • the plurality herein signifies a numerical value corresponding to less than about 30%, preferably less than about 20%, further preferably less than about 10%, still further preferably less than about 5%, and most preferably less than about 1% with respect to the total amino acid. That is to say, the equivalent protein has 80% or more, further preferably about 90% or more, still further preferably about 95% or more and most preferably about 99% or more identity to the amino acid sequence set forth in SEQ ID NO: 5.
  • an equivalent protein is obtained by allowing conservative amino acid substitution to be generated in an amino acid residue that is not essential to the tannase activity.
  • conservative amino acid substitution denotes substitution of an amino acid residue to an amino acid residue having a side chain of the same property.
  • the amino acid residue is classified into some families according to its side chain, for example, the basic side chain (for example, lysin, arginine, and histidine), the acid side chain (for example, asparatic acid, and glutamic acid), the uncharged polar side chain (for example, glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), the nonpolar side chain (for example, alanine, valine, leucine, isoleucine, proline, phenyl alanine, methionine, and tryptophane), ⁇ branched side chain (for example, threonine, valine, and isoleucine), and the aromatic side chain (for example, tyrosine, phenyl alanine, tryptophane, and histidine).
  • the conservative amino acid substitution is carried out between the amino acid residues in the same family.
  • the "equivalent protein” may have an additional property.
  • two sequences The identity (%) between two amino acid sequences or two nucleic acids (hereinafter, referred to as "two sequences" as a term including the both) can be determined by the following procedure. Firstly, two sequences are aligned for optimum comparison of the two sequences (for example, a gap may be introduced into the first sequence so as to optimize the alignment with respect to the second sequence). When a molecule (amino acid residue or nucleotide) at a specific position in the first sequence and a molecule in the corresponding position in the second sequence are the same as each other, the molecules in the positions are defined as being identical.
  • identity (%) number of identical positions / total number of positions ⁇ 100).
  • the number and size of the gaps, which are required to optimize the alignment of the two sequences, are taken into consideration.
  • the comparison and determination of the identity between two sequences can be carried out by using a mathematical algorithm.
  • a specific example of the mathematical algorithm that can be used for comparing the sequences includes an algorithm described in Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68 and modified by Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77 .
  • the algorithm is not necessarily limited to this.
  • Such an algorithm is incorporated in NBLAST program and XBLAST program (version 2.0) described in Altschul et al. (1990) J. Mol. Biol. 215: 403-10 .
  • Gapped BLAST described in Altschul et al., (1997) Amino Acids Research 25(17): 3389-3402 can be utilized.
  • BLAST and Gapped BLAST the default parameters of the corresponding programs (e.g., XBLAST and NBLAST) can be used. In detail, see http://www.ncbi.nlm.nih.gov.
  • Another example of the mathematical algorithm that can be used for comparing sequences includes an algorithm described in Meyers and Miller (1988) Comput. Appl. Biosci. 4: 11-17 .
  • Such programs are incorporated into the ALIGN program that can be used for, for example, GENESTREAM network server (IGH Montpellier, France) or ISREC server.
  • PAM120 weight residue table can be used in which a gap length penalty is 12 and a gap penalty is 4.
  • the identity between two amino acid sequences can be determined by u sing the GAP program in the GCG software package, using Blossom 62 matrix or PAM250 matrix with the gap weight of 12, 10, 8, 6, or 4, and the gap len gth weight of 2, 3, or 4. Furthermore, the homology between two nucleic acid sequences can be determined using the GAP program in the GCG software pa ckage (available at http://www.gcg.com) with the gap weight of 50 and the gap length weight of 3.
  • the present enzyme may be a part of a larger protein (for example, fusion protein).
  • a sequence to be added in the fusion protein may include a sequence useful for purification, for example, a sequence of a multi histidine residue, and an additional sequence for securing the safety for producing a recombinant, and the like.
  • the present enzyme having the above-mentioned amino acid sequence can be prepared easily by a genetic engineering technique.
  • the present enzyme can be prepared by transforming an appropriate host cell (for example, Escherichia coli) by DNA encoding the present enzyme, and by collecting proteins expressed in the transformant. The collected proteins are appropriately purified according to the purposes.
  • an appropriate host cell for example, Escherichia coli
  • various modifications can be carried out. For example, DNA encoding the present enzyme and other appropriate DNA are inserted into the same vector and the vector is used for producing a recombinant protein. Then, the enzyme consisting of a recombinant protein to which arbitrary peptide or protein is linked can be obtained.
  • modification may be carried out so as to cause addition of sugar chain and/or lipid or processing of N-terminal or C-terminal.
  • modification permits extraction of a recombinant protein, simplification of purification, addition of biological functions, or the like.
  • a second aspect of the present invention provides a gene encoding the present enzyme, that is, a novel tannase gene.
  • the gene of the present invention includes DNA encoding the amino acid sequence set forth in SEQ ID NO: 5.
  • a specific example of this embodiment is a DNA consisting of the base sequence set forth in SEQ ID NO: 4.
  • a protein encoded by the modified DNA may sometimes have the equal function to that of a protein encoded by the DNA before modification. That is to say, the modification of the DNA sequence does not have a substantial effect on the function of the encoded protein, so that the function of the encoded protein may be maintained before and after the modification.
  • the present invention provides DNA encoding a protein having a base sequence equivalent to the base sequence set forth in SEQ ID NO: 4 and having the tannase activity (hereinafter, which is also referred to as "equivalent DNA").
  • the “equivalent base sequence” herein denotes a base sequence which is partly different from the base sequence set forth in SEQ ID NO: 4 but in which the function (herein, tannase activity) of the protein encoded by the sequence is not substantially affected by the difference.
  • the equivalent DNA hybridizes to the complementary base sequence of the base sequence of SEQ ID NO: 4 under stringent conditions.
  • stringent conditions are referred to as conditions in which a so-called specific hybrid is formed but a nonspecific hybrid is not formed.
  • Such stringent conditions are known to persons skilled in the art.
  • Such stringent conditions can be set with reference to, for example, Molecular Cloning (Third Edition, Cold Spring Harbor Laboratory Press, New York ) and Current protocols in molecular biology (edited by Frederick M. Ausubel et al., 1987).
  • An example of the stringent conditions can include a condition in which a hybridization solution (50% formamide, 10 ⁇ SSC (0.15 M NaCl, 15 mM sodium citrate, pH 7.0), 5 ⁇ Denhardt solution, 1% SDS, 10% dextran sulfate, 10 ⁇ g/ml denatured salmon sperm DNA, and 50 mM phosphate buffer (pH 7.5)) is used and incubated at about 42°C to about 50°C, thereafter, washed with 0.1 ⁇ SSC and 0.1% SDS at about 65°C to about 70°C.
  • a hybridization solution 50% formamide, 10 ⁇ SSC (0.15 M NaCl, 15 mM sodium citrate, pH 7.0
  • 5 ⁇ Denhardt solution 1% SDS
  • 10% dextran sulfate 10 ⁇ g/ml denatured salmon sperm DNA
  • 50 mM phosphate buffer pH 7.5
  • Further preferable stringent conditions can include, for example, a condition in which a hybridization solution 50% formamide, 5 ⁇ SSC (0.15 M NaCl, 15 mM sodium citrate, pH 7.0), 1 ⁇ Denhardt solution, 1% SDS, 10% dextran sulfate, 10 ⁇ g/ml denatured salmon sperm DNA, and 50 mM phosphate buffer (pH 7.5)) is used.
  • the equivalent DNA can include DNA encoding a protein having a base sequence which includes substitution, deletion, insertion, addition or inversion in one or a plurality of bases when the base sequence of SEQ ID NO: 4 is a reference base sequence, and which has a tannase activity.
  • the substitution, deletion, or the like, of the base may occur in a plurality of sites.
  • the "plurality" herein denotes, for example, 2 to 40 bases, preferably 2 to 20 bases, and more preferably 2 to 10 bases, although it depends upon the positions or types of the amino acid residue in the three-dimensional structure of the protein encoded by the DNA.
  • the above-mentioned equivalent DNA can be obtained by modifying DNA having the base sequence shown in SEQ ID NO: 4 so as to include substitution, deletion, insertion, addition and/or inversion of base by using treatment with a restriction enzyme; treatment with exonuclease, DNA ligase, etc; introduction of mutation by a site-directed mutagenesis ( Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York ) and random mutagenesis ( Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York ), and the like.
  • the equivalent DNA can be also obtained by other methods such as irradiation with ultraviolet ray.
  • a further example of the equivalent DNA can include DNA having difference in base as mentioned above due to polymorphism represented by SNP (single nucleotide polymorphism).
  • the gene of the present invention can be prepared in an isolated state by using a standard genetic engineering technique, a molecular biological technique, a biochemical technique, and the like, with reference to sequence information disclosed in the present specification or attached sequence list.
  • the gene of the present invention can be prepared by appropriately using oligonucleotide probe / primer capable of specifically hybridizing to the gene of the present invention from an appropriate genome DNA library or a cDNA library of Aspergillus awamori, or cell body extract of Aspergillus awamori.
  • An oligonucleotide probe / primer can be easily synthesized by using, for example, a commercially available automated DNA synthesizer.
  • a production method of libraries used for preparing the gene of the present invention see, for example, Molecular Cloning, Third Edition, Cold Spring Harbor Laboratory Press, New York .
  • a gene having the base sequence set forth in SEQ ID NO: 4 can be isolated by using a hybridization method using all or a part of the base sequence or its complimentary sequence as a probe. Furthermore, amplification and isolation can be carried out by using a nucleic acid amplification reaction (for example, PCR) using a synthesized oligonucleotide primer designed to specifically hybridize to a part of the base sequence. Furthermore, it is possible to obtain a target gene by chemical synthesis based on the information of the amino acid sequence set forth in SEQ ID NO: 5 or the base sequence set forth in SEQ ID NO: 4 (see, reference document: Gene, 60(1), 115-127 (1987 )).
  • the present enzyme (tannase) is isolated and purified from Aspergillus awamori, and information about the partial amino acid sequence is obtained.
  • purified tannase is directly subjected to amino acid sequence analysis [protein-sequencer 476A, Applied Biosystems] by Edman Degradation [ Journal of biological chemistry, vol. 256, pages 7990 -7997 (1981 )] according to a routine method. It is effective that limited hydrolysis is carried out by allowing protein hydrolase to act, the obtained peptide fragment is separated and purified, and the thus obtained purified peptide fragment is subjected to the amino acid sequence analysis.
  • a tannase gene is cloned.
  • Cloning can be carried out by using, for example, a hybridization method or a PCR method.
  • a hybridization method for example, a method described in Molecular Cloning (Third Edition, Cold Spring Harbor Laboratory Press, New York ) can be used.
  • PCR reaction is carried out by using a synthesized oligonucleotide primer designed based on the information of the partial amino acid sequence using a genome DNA of a microorganism producing tannase as a template, and thus a target gene fragment is obtained.
  • the PCR method is carried out according to the method described in PCR Technology, edited by Erlich. HA, Stocktonpress, 1989 ].
  • a base sequence is determined by a method usually used in the amplification DNA fragment, for example, a dideoxy chain terminator method
  • a sequence corresponding to the partial amino acid sequence of tannase other than the sequence of the synthesized oligonucleotide primer is found in the determined sequence, and a part of the tannase gene can be obtained.
  • a hybridization method and the like is further carried out by using the obtained gene fragment as a probe, a gene encoding the full length of the tannase can be cloned.
  • a sequence of a gene encoding tannase produced by Aspergillus awamori is determined by using the PCR method.
  • the complete base sequence of a gene encoding tannase produced by Aspergillus awamori is shown in SEQ ID NO: 4.
  • the amino acid sequence encoded by the base sequence is determined (SEQ ID NO: 5).
  • a plurality of the base sequences corresponding to the amino acid sequence set forth in SEQ ID NO: 5 are present.
  • All or a part of the tannase gene (SEQ ID NO: 4) whose complete base sequence has been clarified is used as a probe of hybridization, and thereby DNA having high homology with respect to the tannase gene of SEQ ID NO: 4 can be selected from a genome DNA library or a cDNA library of microorganisms producing other tannase.
  • a primer for PCR can be designed. By carrying out PCR reaction using this primer, a gene fragment having high homology with respect to the above-mentioned tannase gene can be detected and, furthermore, a complete gene thereof can be obtained.
  • Protein of the obtained gene is manufactured, and its tannase activity is measured. Thereby, it is possible to confirm whether or not the obtained gene is a gene encoding a protein having the tannase activity. Furthermore, by comparing the base sequence (or the amino acid sequence encoded thereby) of the obtained gene with the base sequence (or the amino acid sequence encoded thereby) of the above-mentioned tannase gene, the gene structure or the homology may be examined, thereby determining whether or not the gene encodes protein having the tannase activity.
  • modified tannase (a gene subjected to at least one of deletion, addition, insertion, and substitution of one or a plurality of amino acid residues) can be obtained by introduction of random mutation or site-specific mutation. This makes it possible to obtain a gene encoding tannase that has a tannase activity but has different optimum temperature, thermostability, optimum pH, stable pH, substrate specificity, and the like. Furthermore, it becomes possible to manufacture modified tannase by genetic engineering.
  • a scheme for introducing mutation is carried out with consideration of, for example, a characteristic sequence of a gene sequence.
  • the consideration of a characteristic sequence can be made by considering, for example, the prediction of the three-dimensional structure of the protein, and homology to existing proteins.
  • Examples of the method for introducing random mutation include: a method, as method of chemically treating DNA, which causes transition mutation in which sodium hydrogensulfite is allowed to act and cytosine base is converted into uracil base [ Proc. Natl. Acad. Sci.
  • Examples of the method for introducing site-specific mutation include a method using amber mutation [gapped duplex method; Nucleic Acids Res., Vol. 12, No. 24, 9441 - 9456 (1984 )]; a method using a recognition site of the restriction enzyme [ Analytical Biochemistry, Vol. 200, pages 81 - 88 (1992 ), Gene, Vol. 102, pages 67 - 70 (1991 )]; a method using mutation of dut (dUTPase) and ung (uracil-DNA glycosilase) [Kunkel method; Proc. Natl. Acad. Sci.
  • H8-140685 a method by PCR using two types of primers for introducing a restriction enzyme into which the recognition site is added (USP 5,512,463 ); a method by PCP using a double strand DNA vector having inactivated drug-resistant gene and two types of primers [ Gene, Vol. 103, pages 73 - 77 (1991 )]; a method by PCR using amber mutation [International Publication WO98/02535 ], and the like.
  • the site-specific mutation can be easily introduced by using commercially available kits.
  • the commercially available kits include Mutan-G (register trade mark, Takara Bio Inc.) using the gapped duplex method, Mutan-K (register trade mark, Takara Bio Inc.) using the Kunkel method, Mutan - ExpressKm (register trade mark, Takara Bio Inc.) using the ODA method, QuikChangeTM Site-Directed Mutagenesis Kit [STRATAGENE] using a primer for introducing mutation and DNA polymerase derived from Pyrococcus furiosus, and the like.
  • kits using the PCR method for example, TaKaRa LA PCR in vitro Mutagenesis Kit (Takara Bio Inc.), Mutan (register trade mark) - Super Express Km (Takara Bio Inc.), and the like.
  • the primary structure and the gene structure of tannase are provided by the present invention.
  • vector as used in this specification is intended to refer to a nucleic acid molecule capable of transporting nucleic acid that is inserted in the vector to the inside of the target such as cells.
  • the types or forms of vector are not particularly limited. Therefor, examples of the vector may be in a form of a plasmid vector, a cosmid vector, a phage vector, a viral vector (e.g., an adenovirus vector, an adeno-associated virus vector, a retrovirus vector, a herpes virus vector, etc).
  • an appropriate vector is selected.
  • the vector include a vector using Escherichia coli as a host (M13 phage or the modified body thereof, ⁇ phage or the modified body thereof, pBR322 or the modified body thereof (pB325, pAT153, pUC8, etc.) and the like), a vector using yeast as a host (pYepSec1 pMFa, pYES2, etc.), a vector using insect cells as a host (pAc, pVL, etc.), a vector using mammalian cells as a host (pCDM8, pMT2PC, etc.), and the like.
  • the recombinant vector of the present invention is preferably an expression vector.
  • expression vector is a vector capable of introducing the nucleic acid inserted therein into the target cells (host cells) and being expressed in the cells.
  • the expression vector usually includes a promoter sequence necessary for expression of the inserted nucleic acid and an enhancer sequence for promoting the expression, and the like.
  • An expression vector including a selection marker can be used. When such an expression vector is used, by using the selection marker, the presence or absence of the introduction of an expression vector (and the degree thereof) can be confirmed.
  • Insertion of the gene of the present invention into a vector, insertion of the selection marker gene (if necessary), and insertion of a promoter (if necessary), and the like, can be carried out by a standard recombination DNA technology (see, for example, Molecular Cloning, Third Edition, 1.84, Cold Spring Harbor Laboratory Press, New York , a already-known method using restriction enzyme and DNA ligase).
  • the present invention further relates to a transformant into which the gene of the present invention is introduced.
  • the gene of the present invention exists as an exogenous molecule.
  • the transformant of the present invention can be prepared by transfection or transformation using the vector of the present invention mentioned above.
  • the transfection and transformation can be carried out by, for example, a calcium phosphate coprecipitation method, electroporation ( Potter, H. et al., Proc. Natl. Acad. Sci. U.S.A. 81, 7161-7165(1984 )), lipofection ( Felgner, P.L. et al., Proc. Natl. Acad. Sci. U.S.A.
  • Examples of the host cell may include microorganism, animal cells, plant cells, and the like.
  • microorganisms may include bacterial cells such as Escherichia coli, Bacillus sp., Streptomyces sp., and Lactococcus sp.; yeast such as Saccharomyces sp., Pichia sp., and Kluyveromyces sp.; filamentous fungi such as Aspergillus sp., Penicillium sp., and Trichoderma sp.
  • baculovirus may be used as the animal cell.
  • a further aspect of the present invention provides a process for producing tannase.
  • a step of culturing a microorganism selected from the group consisting of Aspergillus awamori and Aspergillus niger (step (1)) and a step of collecting tannase from the culture solution and/or the cell body after the culture (step (2)) are carried out.
  • Aspergillus awamori No. 1725, NBRC-4033 in Table 3
  • Aspergillus niger No. 1332, No. 1349, No. 1363 in Table 3 were found as tannase-producing strains excellent in thermostablity.
  • the step (1) is preferably carried out using one of these microorganisms.
  • the step (1) is more preferably carried out using Aspergillus awamori NBRC-4033 (IFO-4033) that highly produces tannase excellent in thermostability.
  • a culturing method and culturing conditions are not particularly limited as long as the targeted enzyme can be produced. That is to say, a method and culturing conditions which are appropriate for culturing microorganisms to be used can be suitably set on the condition that the present enzyme is produced.
  • the culturing method either of liquid culture or solid culture may be used, but liquid culture is preferably used. As liquid culture is exemplified, the culturing conditions thereof will be explained.
  • a medium containing a carbon source such as glucose, sucrose, gentiobiose, soluble starch, glycerin, dextrin, syrup, and organic acids
  • a nitrogen source such as ammonium sulfate, ammonium carbonate, ammonium phosphate, ammonium acetate, or peptone, yeast extract, corn steep liquor, casein hydrolysate, bran, meat extract, and the like
  • inorganic salts such as potassium salt, magnesium salt, sodium salt, phosphate salt, manganese salt, iron salt, and zinc salt, can be used.
  • vitamin, amino acid, and the like may be added to the medium.
  • Tannic acid can be added to a medium in order to induce production of tannase.
  • the pH of the medium is adjusted to, for example, about 3 to 10, and preferably, about 5 to 6.
  • the culturing temperature is generally about 10°C to 50°C, and preferably about 27°C to 33°C.
  • the culturing is carried out for one to seven days, preferably three to four days under aerobic conditions.
  • a culturing method for example, a shake culture method, and an aerobic submerged culture method with a jar fermenter can be employed.
  • tannase is collected from the culture solution or the cell body (step (2)).
  • the present enzyme can be obtained by separation and purification after removing insoluble matters by, for example, filtration, centrifugation of culture supernatant followed by carrying out any combinations of concentration by ultrafiltration, salting out of ammonium sulfate precipitation, dialysis, various types of chromatography such as ion-exchange resin, and the like.
  • the present enzyme when the present enzyme is collected from the cell body, the present enzyme can be obtained by pulverizing the cell body by pressuring treatment, ultrasonication, and the like, followed by separation and purification thereof similar to the above.
  • the above-mentioned series of processes may be carried out after the cell body is collected from a culture solution by filtration, centrifugation, and the like.
  • the final form may be a liquid state or a solid state (including a powder state). Note here that confirmation of expression or confirmation of expression product can be carried out easily by using an antibody against tannase, but expression can also be confirmed by measuring the tannase activity.
  • tannase is manufactured by using the above-mentioned transformant.
  • the above-mentioned transformant is cultured in the conditions in which the protein encoded by the introduced gene is produced (step (i)).
  • the culture conditions for transformant are well-known, and a person skilled in the art can set appropriate culture conditions easily.
  • a step of collecting the produced protein i.e., tannase
  • Collection and the following purification may be carried out by the same method as mentioned in the above-mentioned embodiment.
  • the present enzyme is provided in a form of, for example, an enzyme preparation.
  • the enzyme preparation may contain, in addition to an active ingredient (the enzyme of the present invention), excipient, buffer agents, suspension agents, stabilizer, preservatives, antiseptics, physiologic saline, and the like.
  • excipient may include lactose, sorbitol, D-mannitol, sucrose, and the like.
  • buffer agent may include phosphate, citrate, acetate, and the like.
  • the stabilizer may include propylene glycol, and ascorbic acid, and the like.
  • Examples of the preservative may include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methyl paraben, and the like.
  • Examples of the antiseptic may include benzalkonium chloride, parahydroxybenzoate, chlorobutanol, and the like.
  • a further aspect of the present invention provides a hydrolysis process of using the present enzyme (or an enzyme preparation containing the enzyme) as an application of the present enzyme.
  • the present enzyme or an enzyme preparation containing the enzyme
  • the present enzyme is allowed to act on tannin or a composition containing tannin.
  • the hydrolysis process of the invention is effective to improvement in quality of foods containing tannin.
  • the hydrolysis process is used for prevention of cream down in tea beverages, prevention of precipitation (lee) and opacity in fruit juice beverages or vegetable juice beverages, beer, or the like.
  • the "tea beverages” herein denote beverages containing an extracted component of tea leaves or plants other than tea leaves.
  • the tea beverages include green tea, black tea, oolong tea, du zhong tea, and herbal tea or the like.
  • the "fruit juice beverages” denote beverages produced using fruit juice obtained by squeeze of fruits.
  • the “vegetable juice beverages” denote beverages produced using vegetable juice.
  • the "beer beverages” include beer, sparkling liquor, and alcoholic beverages having flavors and feeling of a drink similar to those of beer (such as so-called the third category beer that is classified into the other miscellaneous alcohols and liqueurs on liquor tax).
  • drinks to which the hydrolysis process of the present invention is applied are not limited to the above-mentioned examples.
  • the hydrolysis process of the present invention can also be applied to improvement in quality of fruit juice-containing tea beverages, vegetable and fruit juice beverages using fruit juice and vegetable juice, etc.
  • the present enzyme has a stably acting wide pH range as described above. That is, the present enzyme is stable within the range from pH 3.0 to 8.0, and can be used in foods, etc. in mild acid and neutral regions. A pH of a tea beverage is in the neutral region and a pH of a fruit juice beverage is in the mild acid region, and the present enzyme favorably acts on the both beverages. On the other hand, since the optimum temperature of the present enzyme is 60 to 70°C, a reaction can be carried out at the same time of heat extraction from tea leaves, for example. Furthermore, the present enzyme satisfies a demand such that "a reaction at a high temperature is desirable from the viewpoint of corruption prevention".
  • the present enzyme is rapidly deactivated in a general heat sterilization condition (for example, 95°C or higher) in a production step of drinks, and thus, a particular heating step for deactivation of the present enzyme is not required. However, it does not prevent providing the heating step for deactivation of the present enzyme.
  • a general heat sterilization condition for example, 95°C or higher
  • 125 ⁇ L of a 50 mM citric acid buffer solution (pH 5.0) containing 0.17% tannic acid or 10 mM gallic acid esters (methyl gallate, ethyl gallate, propyl gallate, and isoamyl gallate) is added with 125 ⁇ L of an enzyme solution and incubated at 37°C for 30 minutes, followed by adding and mixing 300 ⁇ L of methanol containing 0.667% Rhodanine, and the reaction solution is stood still for 10 minutes. Next, 200 ⁇ L of 0.5 N NaOH is added and mixed and the reaction solution is stood still for 10 minutes.
  • reaction solution is diluted with 9 mL of distilled water and left for 5 minutes, and an absorbance at a wavelength of 520 nm is measured.
  • An analytical curve(standard curve) was formed using gallic acid and an activity that releases 1 ⁇ M of gallic acid for 1 minute is assumed to be 1 unit.
  • thermostable tannase producing microorganism 1. Screening of thermostable tannase producing microorganism
  • thermostable tannase was examined for 5 strains belonging to Aspergillus niger (1332 strain, 1349 strain, 1363 strain, 9331 strain, and 9340 strain) and 3 strains belonging to Aspergillus awamori (1725 strain, 1736 strain, and NBRC-4033 strain). Each strain was cultured at 30°C on a potato dextrose agar medium (Eiken Chemical Co., Ltd.) for 10 to 14 days until preferable spore formation was attained.
  • the spores formed on the obtained colony was scraped with a sterile spore suspension buffer (0.85% NaCl, 0.05% TWEEN (register trade mark) 80) to prepared a spore suspension.
  • the spore suspension was inoculated into the medium of Table 1 and subjected to shake culture at 30°C for 3 days.
  • This culture solution was inoculated into the medium of Table 2 and subjected to shake culture at 30°C for 4 days.
  • each culture supernatant was treated at 65°C for a predetermined time (30 minutes, 60 minutes, and 90 minutes) and a tannase activity was measured by the above-mentioned measurement method of a tannase activity.
  • the measurement results are shown in Table 3.
  • Table 3 the tannase activity (actual measurement values) of each of the culture supernatants after being treated at 65°C for 30 minutes, and treating times and change in the residual tannase activities are shown.
  • the residual activity of a treating time of 60 minutes or 90 minutes was shown as a relative value, assuming the residual activity of a treating time of 30 minutes to be the base (100%).
  • the spore suspension of Aspergillus awamori NBRC-4033 (IFO-4033) shown in 1. was inoculated into the medium of Table 1 and subjected to shake culture at 30°C for 3 days.
  • This culture solution was inoculated into the medium of Table 4 and subjected to shake culture at 30°C for 4 days.
  • the tannase activity of this culture supernatant was 0.35 unit/ml.
  • the obtained culture solution was then filtered off using diatom earth (Fineflow A) as a filtration aid to obtain a filtrate.
  • This filtrate was salted out using an UF module (ACP-2010, Asahi Kasei Corporation) and concentrated.
  • the tannase activity of this concentrated solution was 6.9 unit/ml.
  • [Table 4] (w/v) Glucose 1.0% Gluten meal 0.5% NaNO 3 0.5% KH 2 PO 4 0.2% MgSO 4 0.05% Tannic acid 2.0% pH5.5
  • the concentrated solution was diluted 2 holds with a 20mM citric acid buffer solution (pH 3.5), filtrated with a 0.45 ⁇ m filter, and then supplied in 5 ml of HiTrap TM Sepharose FF equilibrated with the same buffer solution and diluted with a 20 mM citric acid buffer solution containing 1 M NaCl (pH 3.5) in a linear concentration gradient method to obtain a tannase fraction.
  • This tannase fraction was added and dissolved with ammonium sulfate to have a concentration of 3 M and fractionated with 5 ml of HiTrap TM Phenyl HP equilibrated with a 20 mM citric acid buffer solution containing 3 M ammonium sulfate (pH 5.0).
  • the obtained tannase fraction was salted out using a PD-10 column and concentrated by Amicon (register trade mark) Ultra-15 (MWCO 10,000) to obtain a purified enzyme sample.
  • the obtained purified enzyme was subjected to examination of various properties described below and also subjected to an N-terminal amino acid sequence analysis.
  • the purified enzyme was reacted at reaction temperatures of 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C and 80°C.
  • reaction temperatures 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C and 80°C.
  • Each measurement result was shown as a relative activity, assuming a value at a temperature showing the maximum activity as 100% ( Fig. 1 ).
  • the optimum reaction temperature was around 70°C.
  • the optimum reaction pH was measured under the reaction condition of 37°C for 30 minutes in each buffer solution (citric acid buffer solutions at pH 3.0, 3.5, 4.0, 4.5, 5.0, 5.5 and 6.0, and phosphate buffer solutions at pH 6.0, 6.5, 7.0, 7.5 and 8.0) using 1% tannic acid for a substrate. Each measurement result was shown as a relative activity, assuming a value of a pH showing the maximum activity as 100% ( Fig. 2 ). The optimum reaction pH was about 5.5.
  • the purified enzyme was thermally treated for 30 minutes at each temperature of 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C and 80°C in a 50 mM citric acid buffer solution (pH 5.0), and a residual activity was then measured in the above-mentioned measurement method of a tannase activity. Each measurement result was shown as a residual activity, assuming a thermally untreated activity as 100% ( Fig. 3 ).
  • the purified enzyme had 90% or more of a residual activity in the thermal treatment at 65°C for 30 minutes and was stable until 65°C.
  • the purified enzyme was treated in each buffer solution (citric acid buffer solutions at pH 3.0, 3.5, 4.0, 4.5, 5.0, 5.5 and 6.0, and phosphate buffer solutions at pH 6.0, 6.5, 7.0, 7.5 and 8.0) at 30°C for 30 minutes and diluted 5 holds with a 0.2 M acetic acid buffer solution (pH 5.0), and an activity was measured in the above-mentioned measurement method of a tannase activity. Each measurement result was shown as a relative activity, assuming a value of a pH showing the maximum activity as 100% ( Fig. 4 ). The stable pH range was from 3 to 8.
  • a molecular weight marker used was a protein molecular weight marker II (TEFCO), and contained, as standard proteins, Myosin, rabbit muscle (205 KDa), galactosidase, E.
  • TEZCO protein molecular weight marker II
  • Electrophoresis was carried out at 20 mA/gel for about 60 minutes using a gradient gel (Daiichi Pure Chemicals Co., Ltd.) with a gel concentration of 10 to 20% to obtain a molecular weight, and as a result, a wide band appeared at 90,000 to 100,000 Da.
  • the purified enzyme was treated with endoglycosidase H (Roche Co.) and then subjected to SDS-PAGE in the same manner, the molecular weight thereof was about 67 KDa. Accordingly, it was confirmed that the present enzyme has a sugar chain. Further, this molecular weight corresponded to the size that is calculated from a gene sequence disclosed in the present invention.
  • Tannase in a 50 mM citric acid buffer solution (pH 5.0) was added with each 20 mM metallic ion and EDTA, or 0.4M, 0.8M, 2M and 4M urea, respectively, and treated at 30°C for 30 minutes, and an activity was then measured in the above-mentioned measurement method of a tannase activity.
  • the result was shown in Table 5.
  • Each measurement result was shown as a relative activity, assuming the case of no addition as 100%.
  • the activity was not inhibited by metallic ions and EDTA.
  • the activity increased by addition of urea.
  • Substrate specificities to tannic acid and gallic acid esters were measured in the above-mentioned measurement method of substrate specificity.
  • a dissolution activity to tannic acid was assumed to be 100%
  • a dissolution activity of each of the gallic acid esters was 41% for methyl gallate, 30% for ethyl gallate, 29% for propyl gallate, and 27% for isoamyl gallate.
  • Genome DNA was prepared from a cell body of Aspergillus awamori obtained in 2 by the method of Saito and Miura (Biochim. Biophys. Acta, 72, 619-629, 1963 ).
  • the purified sample of tannase obtained in 2 was subjected to an amino acid sequence analysis to determine 7 residues in the N-terminal amino acid sequence (SEQ ID NO: 1).
  • SEQ ID NO: 1 The purified sample of tannase obtained in 2 was subjected to an amino acid sequence analysis to determine 7 residues in the N-terminal amino acid sequence (SEQ ID NO: 1).
  • tannase having a corresponding sequence was searched in BLAST.
  • tannase in which all of the 7 residues were corresponded was only one type of tannase that was Aspergillus niger CBS 513.88 hypothetical protein (An04g04430).
  • a protein derived from the genus Aspergillus in which 7 residues were corresponded was not registered in BLAST.
  • DNA fragment was cloned to pGEM-Teasy (Promega Co.) and the base sequence thereof was then observed, and as a result, a base sequence encoding the partial amino acid sequence mentioned above was found right after the sense primer.
  • the DNA fragment was used as a DNA probe for cloning a full-length gene.
  • a gene library was prepared as follows. A BamHI+XhoI treatment was carried out on the chromosome DNA prepared in (a). 10 ⁇ g of genome DNA of Aspergillus awamori, 5 ⁇ l of a 10 ⁇ K buffer solution, 42 ⁇ l of distilled water, and 3 ⁇ l of BamHI were mixed and the mixture was treated at 30°C for 15 hours.
  • the obtained decomposed product was purified by ethanol precipitation, and then mixed with 5 ⁇ l of a 10 ⁇ H buffer solution, 42 ⁇ l of distilled water, and 3 ⁇ l of XhoI and the mixture was treated at 37°C for 15 hours.
  • the obtained decomposed product was ligated to a pBluescriptII KS(+) (STRATAGENE Corporation) vector, which was treated with BamHI+XhoI in the same manner, to obtain a gene library.
  • the base sequence of a plasmid pBluescriptII-TAN was determined according to a general method.
  • a base sequence (1725 bp) encoding tannase is set forth in SEQ ID NO: 4.
  • An amino acid sequence (574 amino acid residues) encoded by the SEQ ID NO: 4 is set forth in SEQ ID NO: 5.
  • the N-terminal region amino acid sequence (SEQ ID NO: 1) determined in (b) was found.
  • the obtained PCR product was confirmed by electrophoresis and then purified with GENE CLEANE III (15 ⁇ l), thereto were added 5 ⁇ l of a 10 ⁇ L buffer solution, 3 ⁇ l of KpnI and 41 ⁇ L of distilled water and the mixture was treated with an enzyme at 37°C for 6 hours.
  • the obtained decomposed product was purified by ethanol precipitation, and thereto were added 5 ⁇ l of a 10 ⁇ H buffer solution, 3 ⁇ l of EcoT22I and 42 ⁇ L of distilled water and the mixture was treated with an enzyme at 37°C for 15 hours.
  • the obtained decomposed product was confirmed by electrophoresis and purified, and then ligated to an expression vector pTALCPPb (described in Japanese Patent Application Unexamined Publication No. 2003-319786 ), which has been previously treated with KpnI and EcoT22I, to thus obtain an expression plasmid pTALC-TAN ( Fig. 5 ).
  • pTALCPPb has a pyrG gene and a high expression promoter derived from Aspergillus oryzae. Further, it was confirmed that a base sequence encoding tannase in pTALC-TAN was correct.
  • An ABPU1 strain (biA1; pyrG89; wA3; argB2; pyroA4: Mol. Gen. Genet., 253:520-528 [1997 ]) that is an ornithine carbamoyltransferase gene defected strain of Aspergillus nidulans was transformed with an expression plasmid pTALC -TAN.
  • a transformation method was carried out by a method using polyethylene glycol and calcium chloride after forming protoplast ( Mol. Gen. Genet. 218:99-104, 1989 ). 7 strains of transformants obtained as uridine non-requiring strains were cultured in the medium of Table 4 mentioned above.
  • Aspergillus nidulans ABPU1 transformed with pTALCPPb was also cultured as a control in the same manner.
  • the tannase of the present invention has high thermostability such as 90% or more of a residual activity after a treatment at 65°C for 30 minutes and is preferable for applications in which a reaction at a high temperature is desired.
  • Use of the tannase of the invention makes it possible to carry out an enzyme reaction at a high temperature where a fear of contamination is less. Therefore, the tannase of the invention is particularly useful for applications in food processing.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP09821747.4A 2008-10-24 2009-10-02 Tannase, gene encoding same, and process for producing same Active EP2363466B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008274360 2008-10-24
PCT/JP2009/005105 WO2010047047A1 (ja) 2008-10-24 2009-10-02 タンナーゼ、それをコードする遺伝子及びその製造法

Publications (3)

Publication Number Publication Date
EP2363466A1 EP2363466A1 (en) 2011-09-07
EP2363466A4 EP2363466A4 (en) 2012-08-08
EP2363466B1 true EP2363466B1 (en) 2017-05-03

Family

ID=42119103

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09821747.4A Active EP2363466B1 (en) 2008-10-24 2009-10-02 Tannase, gene encoding same, and process for producing same

Country Status (6)

Country Link
US (2) US8617865B2 (ja)
EP (1) EP2363466B1 (ja)
JP (1) JP5719173B2 (ja)
CN (1) CN102203248B (ja)
DK (1) DK2363466T3 (ja)
WO (1) WO2010047047A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103436505B (zh) * 2013-08-13 2014-09-17 广西大学 一种制备单宁酶的方法
CN104004725B (zh) * 2014-06-11 2016-05-11 中国农业科学院饲料研究所 一种中低温中性单宁酶TanXZ7及其基因和应用
CN106834142A (zh) * 2017-03-19 2017-06-13 曹庸 一种产高活力单宁酶菌株的制备方法
US20220175893A1 (en) * 2019-03-05 2022-06-09 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
CN110564746A (zh) * 2019-08-05 2019-12-13 集美大学 一种耐酸型单宁酶及其基因和应用
CN110551702B (zh) * 2019-08-05 2022-07-19 集美大学 重组塔宾曲霉单宁酶及其表达和应用
JP7111317B2 (ja) * 2019-11-20 2022-08-02 株式会社渡辺オイスター研究所 プランクトンからの３、５－ジヒドロキシ－４－メトキシベンジルアルコール（３、５－ｄｉｈｙｄｒｏｘｙ－４－ｍｅｔｈｏｘｙｂｅｎｚｙｌ ａｌｃｏｈｏｌ）の生成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4835478B1 (ja) * 1970-05-18 1973-10-27
JPS4835478U (ja) 1971-08-28 1973-04-27
US5512463A (en) 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
JP3743525B2 (ja) 1994-03-02 2006-02-08 タカラバイオ株式会社 部位特異的変異導入方法
JPH0880196A (ja) 1994-07-12 1996-03-26 Kikkoman Corp タンナーゼ遺伝子を含有するｄｎａ断片、新規な組み換え体プラスミド、タンナーゼの製造方法およびプロモーター
JPH0835478A (ja) 1994-07-22 1996-02-06 Takashi Nishi 水の流れによる発電装置
JP3526326B2 (ja) 1994-09-05 2004-05-10 タカラバイオ株式会社 部位特異的変異導入方法
JPH08140685A (ja) 1994-11-22 1996-06-04 Takara Shuzo Co Ltd 部位特異的変異導入方法
WO1998002535A1 (fr) 1996-07-11 1998-01-22 Takara Shuzo Co., Ltd. Procede pour effectuer une mutagenese dirigee
US20030170846A1 (en) * 2000-04-24 2003-09-11 Weisgerber David John Enzyme variants having one or more D-amino acid substitutions
US20030082595A1 (en) * 2001-08-03 2003-05-01 Bo Jiang Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use
US7186540B2 (en) * 2001-12-27 2007-03-06 National Institute of Advanced Indusrtial Science and Technology Thermostable glutaminase and thermostable glutaminase gene
JP4370395B2 (ja) 2001-12-27 2009-11-25 独立行政法人産業技術総合研究所 タンナーゼ、その遺伝子及びタンナーゼの製造法
JP4495904B2 (ja) 2002-03-01 2010-07-07 天野エンザイム株式会社 改変プロモーター
DE102004032216A1 (de) * 2004-07-02 2006-01-26 Institut für Pflanzengenetik und Kulturpflanzenforschung Polypeptide mit Tannase- und/oder Lipase-Aktivität
EP1837400A1 (en) * 2005-01-05 2007-09-26 Eisai R&D Management Co., Ltd. Novel tannase gene and protein thereof
CN101260392A (zh) 2008-04-17 2008-09-10 贵州大学 一种用五倍子生料固体发酵生产单宁酶的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAGAI MASARU ET AL: "Purification and characterization of an endo-polygalacturonase from Aspergillus awamori", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, TOKYO, JAPAN, vol. 64, no. 8, 1 August 2000 (2000-08-01), pages 1729 - 1732, XP002471742, ISSN: 0916-8451, DOI: 10.1271/BBB.64.1729 *
SATOSHI KANEKO ET AL: "Purification and Substrate Specificities of Two [alpha]-l-Arabinofuranosidases from Aspergillus awamori IFO 4033", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1 October 1998 (1998-10-01), UNITED STATES, pages 4021 - 4027, XP055261455, Retrieved from the Internet <URL:http://aem.asm.org/content/64/10/4021.full.pdf> [retrieved on 20160330] *

Also Published As

Publication number Publication date
US8911984B2 (en) 2014-12-16
EP2363466A4 (en) 2012-08-08
DK2363466T3 (en) 2017-07-03
JP5719173B2 (ja) 2015-05-13
WO2010047047A1 (ja) 2010-04-29
CN102203248A (zh) 2011-09-28
US8617865B2 (en) 2013-12-31
US20140093939A1 (en) 2014-04-03
EP2363466A1 (en) 2011-09-07
JPWO2010047047A1 (ja) 2012-03-15
US20110195155A1 (en) 2011-08-11
CN102203248B (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
US8911984B2 (en) Tannase, gene encoding same, and process for producing same
EP2439270B1 (en) Galactosidase derived from bacillus circulans
EP2295563B1 (en) Beta-amylase, gene coding therefor and manufacturing method thereof
US11142748B2 (en) Saccharide oxidase, and production method for same and use of same
EP2454942B1 (en) Method for improvement of foods utilizing beta-amylase
EP2022850B1 (en) Flavin adenine dinucleotide-binding glucose dehydrogenase
KR20120103545A (ko) 말토트리오실 전이효소, 그 제조 방법 및 용도
US9974318B2 (en) Method for producing a low-lactose milk, medicine, supplement, or galacto-oligosaccharide
US11078470B2 (en) Nucleosidase
JP7360951B2 (ja) 夾雑活性が低減したヌクレオシダーゼ剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101AFI20120626BHEP

Ipc: C12N 5/10 20060101ALI20120626BHEP

Ipc: C12N 9/18 20060101ALI20120626BHEP

Ipc: C12N 1/21 20060101ALI20120626BHEP

Ipc: C12N 1/19 20060101ALI20120626BHEP

Ipc: C12P 7/40 20060101ALI20120626BHEP

Ipc: C12N 1/15 20060101ALI20120626BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120705

17Q First examination report despatched

Effective date: 20130722

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170104

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20170317

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 890015

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009045916

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170628

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 890015

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170503

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170804

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170803

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170803

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009045916

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171002

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230512

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230915

Year of fee payment: 15

Ref country code: GB

Payment date: 20230831

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230911

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20231016

Year of fee payment: 15

Ref country code: DE

Payment date: 20230830

Year of fee payment: 15